RxDoctor Payments DataLook up a doctor →

Elizabeth Cull, MD

Hematology & Oncology · Greenville, SCNPI 1356674527

Payments from drug & device makers

$1,207,973in general payments, 2019–2025

Across 236 payments — averaging $5118.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aptevo Therapeutics Inc$265K
  • Genentech, Inc.$238K
  • Seagen Inc.$197K
  • Merck$122K
  • E.r. Squibb & Sons, L.L.C.$109K
  • Bristol Myers Squibb$92K
  • plus $185K from 37 others

What the payments were for

  • Consulting fees$1,69511%
  • Speaking & faculty fees$10,63167%
  • Travel & lodging$1,2958%
  • Food & beverage$2,09913%
  • Education$1171%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,207,973 in reported general payments places this provider in the 95th percentile of 166 hematology & oncology providers in South Carolina.

See all hematology & oncology providers in South Carolina

Medicare billing

Part B allowed, 2024
$98,272
Medicare patients
339
Services billed
1,719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide119$1,967,790
Lenalidomide56$800,887
BrukinsaZanubrutinib57$727,276
TasignaNilotinib Hcl52$702,057
CalquenceAcalabrutinib Maleate40$603,409
JakafiRuxolitinib Phosphate32$524,680
PomalystPomalidomide24$467,420
ImbruvicaIbrutinib21$299,753
InqoviDecitabine/Cedazuridine32$261,014
VenclextaVenetoclax48$202,343
BosulifBosutinib11$155,620
Posaconazole46$80,412
PegasysPeginterferon Alfa-2a12$52,375
EliquisApixaban41$25,676
Atovaquone26$16,232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$91,998$1,967,790119 claims
Beigene USA, Inc.Brukinsa$34$727,27657 claims
NovartisTasigna$240$702,05752 claims
AstraZenecaCalquence$33,306$603,40940 claims
Incyte CorporationJakafi$15$524,68032 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$109,327$467,42024 claims
AbbVieVenclexta$14,146$202,34348 claims
PfizerBosulif, Eliquis$275$181,29652 claims
Genentech, Inc.Pegasys$237,543$52,37512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 166 hematology & oncology providers in South Carolina.

Other hematology & oncology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →